 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Abgenix, Inc.
 |
Abgenix, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Abgenix reports wider-than-expected Q2 loss Jul 24 2001 01:42 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Here comes XenoMouse to save the day! Abgenix uses genetically engineered mice to develop antibody therapeutics for inflammatory and autoimmune disorders, cancer, and transplant-related conditions. The company's four antibody product candidates use the XenoMouse technology, which Abgenix bought from Japan Tobacco. Treatments for transplant-rejection disorders, cancer, and psoriasis are in clinical trials. Abgenix has caught the eye of major biotech players; among the notables with which it is allied are Millennium Pharmaceuticals, Pfizer, and Amgen. Cell Genesys spun off Abgenix in 1996 and still retains more than 10%.
COMPETITION |
 |
ImClone Systems Incorporated (IMCL)
Medarex, Inc. (MEDX)
Protein Design Labs, Inc. (PDLI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 26.60
1-Yr. Sales Growth: 116.3%
Employees: 174
Revenue per employee: $152,873.56
KEY PEOPLE |
 |
R. Scott Greer
CEO
Kurt W. Leutzinger
CFO
CONTACT INFO |
 |
7601 Dumbarton Circle
Fremont, CA 94555
US
Phone: 510-608-6500
Fax: 510-608-6511
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |